Renaissance Technologies (RenTech)'s OVID Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 105,500 shares of Ovid Therapeutics Inc. (OVID) worth $283,795, representing 0.00% of the portfolio. First purchased in 2018-Q4, this long-term strategic position has been held for 30 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in OVID, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 1.07 M shares. Largest reduction occurred in Q2 2026, reducing 998,800 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Ovid Therapeutics (OVID) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ovid Therapeutics (OVID) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -998,800 | Reduce 90.45% | 105,500 | $2.69 |
| Q1 2026 | -380,178 | Reduce 25.61% | 1.1 M | $2.22 |
| Q4 2025 | -533,546 | Reduce 26.44% | 1.48 M | $1.63 |
| Q3 2025 | -77,285 | Reduce 3.69% | 2.02 M | $1.30 |
| Q2 2025 | +1.07 M | Add 104.66% | 2.1 M | $0.33 |
| Q1 2025 | +916,100 | Add 850.60% | 1.02 M | $0.31 |
| Q4 2024 | +63,200 | Add 142.02% | 107,700 | $0.93 |
| Q3 2024 | -96,700 | Reduce 68.48% | 44,500 | $1.18 |
| Q2 2024 | -15,600 | Reduce 9.95% | 141,200 | $0.77 |
| Q1 2024 | +105,600 | Add 206.25% | 156,800 | $3.05 |
| Q4 2023 | -29,600 | Reduce 36.63% | 51,200 | $3.22 |
| Q3 2023 | -33,900 | Reduce 29.56% | 80,800 | $3.84 |
| Q2 2023 | -5,900 | Reduce 4.89% | 114,700 | $0.00 |
| Q1 2023 | +800 | Add 0.67% | 120,600 | $0.00 |
| Q4 2022 | +1,000 | Add 0.84% | 119,800 | $0.00 |
| Q3 2022 | -5,000 | Reduce 4.04% | 118,800 | $1.84 |
| Q2 2022 | +39,000 | Add 45.99% | 123,800 | $2.15 |
| Q1 2022 | +26,200 | Add 44.71% | 84,800 | $3.14 |
| Q4 2021 | +24,100 | Add 69.86% | 58,600 | $3.21 |
| Q3 2021 | +34,500 | New Buy | 34,500 | $3.36 |
| Q1 2021 | -710,507 | Sold Out | 0 | $0.00 |
| Q4 2020 | +710,507 | New Buy | 710,507 | $2.31 |
| Q3 2020 | -624,109 | Sold Out | 0 | $0.00 |
| Q2 2020 | -228,734 | Reduce 26.82% | 624,109 | $7.37 |
| Q1 2020 | -231,866 | Reduce 21.38% | 852,843 | $2.98 |
| Q4 2019 | +497,984 | Add 84.88% | 1.08 M | $4.15 |
| Q3 2019 | +115,116 | Add 24.41% | 586,725 | $3.24 |
| Q2 2019 | +108,392 | Add 29.84% | 471,609 | $1.85 |
| Q1 2019 | +308,117 | Add 559.20% | 363,217 | $1.77 |
| Q4 2018 | +55,100 | New Buy | 55,100 | $2.41 |
Renaissance Technologies (RenTech)'s Ovid Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Ovid Therapeutics Inc. (OVID) in Q4 2018, acquiring 55,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Ovid Therapeutics Inc. (OVID) for 30 quarters since Q4 2018.
Renaissance Technologies (RenTech)'s largest addition to Ovid Therapeutics Inc. (OVID) was in Q2 2025, adding 2,095,309 shares worth $691,242.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 105,500 shares of Ovid Therapeutics Inc. (OVID), valued at approximately $283,795.
As of the Q2 2026 filing, Ovid Therapeutics Inc. (OVID) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Ovid Therapeutics Inc. (OVID) was 2,095,309 shares, as reported at the end of Q2 2025.